Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GMP Warnings Split Between Brand, Generic Firms; Congress Watches FDA

Executive Summary

The number of prescription drug manufacturing warning letters from FDA remained roughly split between brands and generics during the last year, but brands dominated the citations in early 2008, in contrast to generics' dominance since mid-year, when the House Energy and Commerce Committee launched an investigation into the agency's handling of products produced by Ranbaxy
Advertisement

Related Content

Generics Industry Faces Five Major Challenges, Actavis CEO Says (We're Partly Responsible For One Of Them, He Acknowledges)
Import Safety Legislation: Generic Firms Could Accept Fees, Not Delays
Import Safety Legislation: Generic Firms Could Accept Fees, Not Delays
Globalization Bill Creates Fees For Generic Pre-approval Inspections
Baxter’s War Games: Post-Heparin, Scientists Consider Supply Chain Threats
Baxter’s War Games: Post-Heparin, Scientists Consider Supply Chain Threats

Topics

Advertisement
UsernamePublicRestriction

Register

PS050723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel